



World Precision Medicine (China) Summit 2016

Gaining a Clearer Perspective into Innovation Trends, Technology Advancements and Cooperation Opportunities

Shanghai Everbright International Hotel

Dec 3rd-4th Shanghai , China

Co-organized by:



枫林集团
FENGLIN L&H



中美药协
SAPA




万怡会展
HEALIFE GROUP

Recommended by:



ESTRO
European Society for
RADIOTHERAPY
& ONCOLOGY

Endorsed by:



U.S. CHINESE
ANTI-CANCER ASSOCIATION



中国精准医疗产业技术创新战略联盟
CHINA PRECISION MEDICINE TECHNOLOGY INNOVATION STRATEGIC ALLIANCE

Part of Eminent Sponsors:



Agilent Technologies



RAININ
Pipetting 360°



NovelBio

EDGC
EONE-DIAGNOSTICS
Genome Center



海云基因
OceanCloud Gene



云健康
CLOUD HEALTH



"Doctors have always recognized that every patient is unique, and doctors have always tried to tailor their treatments as best they can to individuals. You can match a blood transfusion to a blood type — that was an important discovery. What if matching a cancer cure to our genetic code was just as easy, just as standard? What if figuring out the right dose of medicine was as simple as taking our temperature?"

- President Obama, January 30, 2015

+ FORUM BACKGROUND

Dear Folks,

On January 30, 2015, US President Obama launched the Precision Medicine Initiative and precision medicine has become the spotlight of global healthcare industry. Meanwhile, Chinese President Xi Jinping appointed the NHFPC and the MOST to establish the National Precision Medicine Strategic Expert Committee. Chinese Precision Medicine Plan has been included in the 13th FYP for national major science & technology specific projects and precision medicine has become China's national strategy. Currently, global precision medicine market values about \$60 billion and the growth rate is estimated up to 15% from 2015 to 2020, which equals almost 3-4 times of the entire pharmaceutical industry. Stimulated by favorable policies and funding environment, and with the rapid technology advancements of NGS, gene editing, biochip, IVD, liquid biopsy, anti-body drugs R&D, cell immunotherapy, big data and inspiring research breakthroughs, precision medicine industry is embracing new development opportunities.

In such context, "World Precision Medicine (China) Summit 2016", co-organized by Sino-American Pharmaceutical Professionals Association (SAPA), Shanghai Fenglin life Healthcare Development Co., Ltd. and Healife Group will be held on December 3-4, 2016 in Shanghai, China. Under the theme of "Gaining a Clearer Perspective into Innovation Trends, Technology Advancements and Cooperation Opportunities", WPMCS2016 brings together 1,000+ senior executives from Government, academy, hospitals, big pharmas, life sciences & biotech companies, CROs, VCPEs to discuss the redhot topics such as China-US precision medicine market outlook and evolving regulatory landscape, big data, advanced technologies and investment opportunities, biobank & cohort study, cell immunotherapy, genetic testing & IVD, innovation & cooperation of antibody drugs, clinical therapy of tumor. Geographically, besides the delegates from Mainland China, a large number will be travelling from the United States, Europe, Israel, Japan, Korean, Singapore, Taiwan and many other countries and areas. WPMCS2016 offers an ideal balance of scientific sessions and networking opportunities, and features 200+ one-to-one meetings, 100+ eminent speakers from global precision medicine fraternity, 50+ exhibitors, 5 parallel symposiums, 2 interactive panel discussions, 1 project financing roadshow matching and our specially designed post-event US precision medicine overseas business trip.

We are looking forward to meeting you at WPMCS2016 this December in Shanghai!

Chairman



Weiguo Dai, Ph.D,
SAPA President

Johnson and Johnson Scientific Director/Janssen Fellow/ AAPS Fellow
On behalf of the WPMCS2016 Organizing Committee

+ YOU WILL GET

- Hear insights from world's leading figures on precision medical trends
- Showcase your products and solutions ,meet 600+ representative and generate new business
- Improve your brand awareness and gain investment
- Access to the panel discussions where you are free to talk publicly

+ FORUM FEATURES

- 1000+** Senior Participant from Global Precision Medicine Fraternity
- 500+** Senior Representatives from Big Pharma/Biotech/ Life Science/Research Institutions
- 200+** One-to-One Meetings
- 100+** World-class Eminent Speakers
- 50+** Exhibitors
- 5** parallel symposiums
- 1** Special Designed Half-day Project Financing Roadshow Matching
- PLUS** post-event US precision medicine business trip

+ WHO WILL ATTEND

The World Precision (China) Summit 2016 is an exclusive event designed for senior level attendees from leading pharmaceuticals, biotechnologies, diagnostics, CROs and IT solution providers, along with highly esteemed members of academic and government bodies. Geographically, besides the delegates from Mainland China, a large number will be travelling from Taiwan, Hong Kong, other Asian countries (Japan, Singapore, Korean, India, Malaysia, Australia, Thailand, Indonesia, and Philippines), Israel, Europe, and the United States. This diversity will allow a strong exchange of opinions and ideas.

Industry Segment:



Job Title Breakdown:



Geographic Segment:



+ PART OF CONFIRMED SPEAKERS



Weiguo Dai

SAPA President

Johnson and Johnson Scientific Director
Janssen Fellow, AAPS Fellow



Wang Hongyang

Academician Vice President

The Third Hospital of the
Second Military Medical University



Wang Jian

Chairman
BGI



Carl Li

Managing Director, Greater Asia
Intel Health and Life Science Group



Zhang Lianshan

Vice President of Global R&D
Jiangsu Hengrui Medicine Co., Ltd



Shao Liming

Director
Shanghai Center for Drug
Discovery & Development



Liu Baorui

Vice President
The Affiliated Hospital of Nanjing
University Medical School



Dr. Jim Vaught

Past President
ISBER



David Smith

Professors
Mayo



Zeng Jimeng

Professor &
Executive Director
TMRC, CTCTCT



Liang Han

Tenured Associate Professor
University of Texas MD
Anderson Cancer Center



Guo Hongyan

Associate Researcher
CapitalBio Corporation



Ruilin Zhao

General Manager
of Greater China
Illumina



Zhan Xianquan

Professor
Xiangya Hospital
Central South University



Kevin Chen


Partner
Sequoia Capital



Wang Haijiang


Executive Partner
GTJA Investment

+ AGENDA FRAMEWORK



+ MEDIA PARTNERS

Why to Attend?



Dec, 3
Day One
AM

Plenary Session: China –US Precision Medicine Market Outlook and Evolving Regulatory Landscape

Moderator: Dai Weiguo, Chairman, SAPA

08:00~09:00 Registration

09:00~09:25 What's in the Regulatory Pipeline? – Unveiling China's Precision Medicine Development Strategy during the 13th Five-Year-Plan

Wu Zhen

Deputy Director

China Food and Drug Administration (CFDA)

09:25~09:50 Creating an Environment Conducive to Innovation: Incentives & Implications

Chen Chuanhong

Director, Department of S&T for Social Development

Ministry of Science and Technology PRC

09:50~10:15 Introduction of US PMI and Draft Guidance on NGS-based Tests by FDA

Francis Collins Ph.D

Director

National Institutes of Health (NIH)

10:15~10:40 Global Antibody Drug Innovation: China's Role and Government's Perspective

Leigh Verbois Ph.D

Director

FDA China Office

10:40~11:00 Networking Tea Break (Interactive Exhibitions/One-to-one Meetings) 

11:00~11:30 Innovation & Cooperation: Capturing Growth of China's Booming Precision Medicine Market

Wang Jian

Chairman

BGI

11:30~12:00 The Development Prospect of China Health Life Industry

Wu Yinfei

Chairman

Shanghai Fenglin Life Healthcare Development Co., Ltd.

12:00~ 12:30 Topic to be Confirmed

Thermo Fisher Scientific

12:30~13:30 Networking Luncheon (Interactive Exhibitions/One-to-one Meetings) 

Dec, 3
Day One
PM

Plenary Session: Big Data, Advanced Technologies and Investment Opportunities

Moderator: Yang Zhi

Founding Partner, BVCF Fund

13:30-14:00 Harnessing Value from Innovative Big Data Platform for Cancer Bioinformatics

Wang Ping

President, Tianjin Medical University Cancer Institute & Hospital

Director, Big Data Center for Precision Medicine

14:00-14:30 Science and Technology, Restarting the New Life – Watson for Oncology Expert Boosts Efficient Normalized Tumor Treatment

Wu Yiduo Head of Watson Health China

CTO Innovation Division, IBM

14:30-15:00 Industrial Revolution of Precision Medicine based on Big Data

Chen Runsheng Academician

Researcher

Institute of Biophysics, Chinese Academy of Sciences

15:00-15:30 Innovative Solutions of Cloud Based Genome Analysis

Hu Xiaoming Vice President, Alibaba Group

President, Alibaba Cloud Computing

15:30-16:00 Adopting Advanced Big Data Analysis Tools in Precision Medicine Research and Clinical Treatment

Carl Li

General Manager Asia-Pacific Region

Intel Health and Life Sciences at Intel Corporation

16:00- 16:10 Innovation Entrepreneurship of Global Precision Medicine

Yang Hongfei Founder& CEO Firestone

16:00~16:30 Networking Tea Break (Interactive Exhibitions/One-to-one Meetings) 

16:30~17:30 Interactive Panel Discussion I:

How will "Internet + Big Data" Transform the Precision Medicine Industry?

Moderator:

Gan Rongxing Director, Shanghai Clinical Research Center

Panelists:

Li Yixue Director, Shanghai Center for Bioinformation Technology

Wang Jian Chairman BGI

Hu Xiaoming Vice President, Alibaba Group, President, Alibaba Cloud Computing

Carl Li, General Manager Asia-Pacific Region, Intel Health and Life Sciences at Intel Corporation

Wu Yiduo Head of Watson Health China, CTO Innovation Division, IBM

17:30~18:30 Interactive Panel Discussion II:

Where is the Next El Dorado? - Unveiling Precision Medicine Investment Strategies

Moderator:

Yang Hongfei Founder& CEO Firestone

Panelists:

Zhao Ruilin General Manager Illumina China

Chen Penghui Partner, Sequoia Capital

Yu Tiecheng Partner V-stone Investment

Wang Haijiao Executive Partner GTJA Investment Group

18:40~20:00 VIP Dinner 

Dec, 4
Day Two
AM

**Parallel Symposium I:
Genetic Testing & IVD**
Session Chair: Wei Zhang Ph.D.
Chairman, USCACA

08:30~09:00 Registration

09:00~09:20 Advanced Biochip Technologies Innovation and Application
Guo Hongyan, *Associate Researcher* CapitalBio Corporation

09:20~09:40 Market Analysis on Global IVD industry and Chinese Opportunity
Fatt-heng WONG, *CEO*, Roche Diagnostics Greater China

09:40~10:00 High-throughput Sequencing Applied to Precise Treatment of Tumor
Boris Pasche, *Director*, Wake Forest University Baptist Comprehensive Cancer Center (To Be Confirmed)

10:00~10:15 Biomarkers and CDx – the First Half of Precision Medicine
Nick Zhang, *General Manager*, Qiagen

10:15~10:30 Pathways to a Healthier World - In-Vitro Diagnostics, Genetic Testing, Clinical Trials and Data Protection
Denis Horgan, *Executive Director*, EAPM

10:30~10:45 Networking Tea Break
(Interactive Exhibitions/One-to-one Meetings)



10:45~11:00 China “Healthy Dream”: Application and Feedbacks from Genetic Testing in Precise Tumor Therapy
Wu Yilong
Vice President, Guangdong General Hospital
Director, Guangdong Lung Cancer Institute

11:00~11:15 Pathology is the Foundation of The Precise Medicine, Molecular Diagnosis and Precision Medicine
David Smith, *Chairman*, Technology Assessment Group (TAG), Center for Individualized Medicine, Mayo Clinic

11:15~11:30 Subversive Innovation: Application of the Second Generation Sequencing, Accurate and New Drug Development
Wang Lei, *President*, Astrazeneca China

11:30~11:45 The Recent Developments in Cancer Liquid Biopsy Technique
Han Yushen, *Founder& CEO*, Burning Rock DX

11:45~12:00 Precision Medicine, Accurate Medicine Expenses- Genetic Diagnosis' Contribution in Optimizing Medical Costs

12:00~12:15 Molecular diagnostic new technology platform's Development, Introduction and Application

12:15~12:45 Hot issues, Further dialogue:
Calmness after Explosive Innovation: Promote The Standardization Gene Sequencing Development, Rational Application Of The Second Generation Sequencing Technology
In Precision Medicine Industry, what the Role of Pathology plays in Multidisciplinary?
Discussion of Gene Sequencing Current Situation and Future Realization: Standardization? Administrative Examination and Approval Rate? Health Care Insurance Access?
Cross-Border Cooperation: The Possibility Of China Genetic Data
Moderator: Zhang Wei, *Chairman*, USCACA
Panelists: Fatt-heng WONG, Wu Yilong, Han Yusheng, Wang Lei, David Smith

12:45~13:45 Networking Luncheon
(Interactive Exhibitions/One-to-one Meetings)



Dec, 4
Day Two
AM

**Parallel Symposium II:
Clinical Therapy of Tumor**
Session Chair: Zhan Xianquan Professor,
Ministry of Health, Xiangya Hospital Central South University, Key Laboratory of Cancer Proteomics

08:30~09:00 Registration

09:00~09:30 Precision Medicine Era: Facing the Challenge of Cancer
Fan Jia *President*, Zhongshan Hospital Fudan University

09:30~10:00 Tumor Heterogeneity and Individualized Treatment
Wang Hongyang *Academician Vice President*, The Third Hospital of the Second Military Medical University

10:00~10:30 Under The Background of Big Data, Medical Research Innovation and Application Into Practice & Thinking
Zhao Jun, *Vice President*, Jiangsu Province Hospital

10:30~10:45 Networking Tea Break
(Interactive Exhibitions/One-to-one Meetings)



10:45~11:15 The Individualized Treatment of Lung Cancer
Paul A. Bunn, *Distinguished Professor*, Division of Medical Oncology/University of Colorado, *president* in Lung Cancer Research

11:15~11:30 Individualized Clinical Thinking of Cancer Immune Therapies
Liu Baorui
Vice President, The Affiliated Hospital of Nanjing University Medical School *Director*, Tumor Center,

11:30~11:45 Big Data Mining for Precision Oncology
Liang Han *Tenured Associate Professor*, University of Texas MD Anderson Cancer Center

11:45~12:00 The Adoption of Proteome Variation in the Process of Cancer Prediction, Prevention, Diagnosis and Evaluation
Zhan Xianquan *Professor*, Ministry of Health, Xiangya Hospital Central South University, Key Laboratory of Cancer Proteomics

12:00~12:15 Clinical Practice of Cancer Precise Treatment
Zeng Jimeng *Professor & Executive Director*, TMRC, CTCTCT

12:15~12:45 Multidisciplinary Cooperation to Build New Tumor Individualized Treatment Technology

12:45~13:45 Networking Luncheon
(Interactive Exhibitions/One-to-one Meetings)



Dec, 4
Day Two
AM

**Parallel Symposium III:
Innovation & Cooperation of Antibody Drugs**
Moderator: Xia Mingde Ph.D.
Senior Director, Asia-Pacific Innovation Center
Johnson & Johnson

08:30~09:00 Registration

09:00~09:30 Drug Discovery Innovation: New Normal of Chinese Pharmaceuticals
Shao Liming *Director*
Shanghai Center for Drug Discovery & Development
Distinguished Professor, National "Thousand Talents Program"

09:30~10:00 Biological Macromolecular Medicine Research Development Progress and Hengrui's Experience
Zhang Lianshan *Vice President of Global R&D*, Jiangsu Hengrui Medicine Co, .Ltd

10:00~10:30 Topic to Be Confirmed
LinkChem Shanghai Co., Ltd.

10:30~10:45 Networking Tea Break
(Interactive Exhibitions/One-to-one Meetings)



10:45~11:15 The Market Prospect and Industrialization Strategy of China Monoclonal Antibody Drugs
Wang Junlin *President*, CP Guojian Pharm

11:15~11:45 The Recent Advances of Global Antibody-drug Conjugate
Jonathan Drachman *CMO & EVP*, Research and Development, Seattle Genetics

11:45~12:15 The Success Factor of Tumor Antibody Drug Development and Clinical Trial
Labcorp/Wuxi AppTec

12:15~12:45 External Innovation Cooperation And Technology Transfer Of Intellectual Property Protection Strategy

12:45~13:45 Networking Luncheon
(Interactive Exhibitions/One-to-one Meetings)



**Parallel Symposium IV:
Biobank & Cohort Study**
Session Chair: Huang Jufang, Party Secretary, School
Basic Medical Science Central South University

Dec, 4
Day Two
PM

13:45~14:15 High Quality Biological Sample Acquisition Process and Quality Control System under the International Standards

Jim Vaught *Past-President, ISBER*

14:15~14:45 Genetic Susceptibility To Disease

Jin Li *Vice President, Fudan University*

14:45~15:15 The Current Construction Situation Analysis and Application Prospect of China Tumor Bio Bank

Ning Guang *Vice President, Ruijin Hospital*

**15:15~15:30 Networking Tea Break
(Interactive Exhibitions/One-to-one Meetings)**



15:30~16:00 Forecasting and Monitoring the Critical Diseases by Ultra-Large Cohort Study

Li Liming *Professor, Peking University Public Health Medical College*

16:00~16:30 The Adoption of Bio Bank in Precision Medicine

Liu Lei *Professor, Biomedical Research Institute Of Fudan University*

16:30~17:00 Biological samples library innovative solutions of cloud BIMS

17:00~17:30 The Biobank Management Information System with technical innovation

End

Parallel Symposium V:Cell Immunotherapy
Session Chair: Han Weidong Professor
Chief of Immunity Dept. 301 Hospital

Dec, 4
Day Two
PM

13:45~14:15 AABB International Standard and US Clinical Application Development Status of Cord Blood
Naynesh Kamani, MD, Vice President, Center for Cellular Therapies & Research

14:15~14:45 Topic To Be Confirmed

Yehia Abugabal, Founder, ICRC

14:45~15:15 CAR-T Cell Therapy Clinical Risk Prevention at the Present Stage and Future Application Prospect
Xu Guotong *President Wuhan Tongji Hospital*

**15:15~15:30 Networking Tea Break
(Interactive Exhibitions/One-to-one Meetings)**



15:30~16:00 A New Generation of PD - L1 Antibody's Broad Application Prospects in Tumor Immunotherapy

16:00~16:30 CAR-T Clinical Application in B Lymphoblastic Leukemia

**16:30~17:30 Interactive Panel Discussion
Medical Technology Regulation-- Cellular Immune Treatment Industry's Development Opportunities and Challenges In China**

- The Problems in The Cellular Immune Technology Application And Development Prospects
- International Medical Technology Management From Europe And The United States And Japan And South Korea
- How Government Regulate Medical Technology Clinical Application
- The New Development Trend of Drug Industry under the New National Drug Regulation

Moderator:

Han Weidong *Professor Chief of Immunity Dept. 301 Hospital*

Panelists:

Qian Qijun *Head of Diagnosis and Treatment of Tumor Biological Treatment Center, The Second Military Medical University*

Maxu, *Head of Institute, Health Development Planning*

Commission of Science and Technology Institute

Chen Yingyao, *Vice President Fudan university school of public health, Director The ministry of health of health technology assessment key laboratory*

Xu Guotong *President Wuhan Tongji Hospital*

End

**Parallel Symposium VI:
Project Financing Roadshow Matching**
Session Chair: Li Min
General Manager, Investment Department
Healife Group

Dec, 4
Day Two
PM

13:45~17:30 (6 Selected Projects Only, 20-min + Q&A)

At this half-day roadshow session which focusing on **gene sequencing, biochip, liquid biopsy, anti-body drugs, and cellular immunotherapy** etc., 6 selected entrepreneurs will present their innovative projects to 100+ investors who are looking for GREAT PROJECTS. It's an ideal financing & investment cooperation platform.



How to Participate?

Step1, Submit your BP to wpmcs@qq.com by **October 31th, 2016**
Step2, **Assessment** by judges from **November 1 to November 18, 2016**

Step3, Inform shortlisted companies and sign FA by **November 25th, 2016**

Step4, Finalize the road show companies and investors list by **November 30th, 2016**

Step5, Beforehand roadshow guidance, Onsite Presentation and investment investigation during **December 2016**

